• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Nonhematologic Malignancy - Pipeline Review, H2 2012 Product Image

Nonhematologic Malignancy - Pipeline Review, H2 2012

  • ID: 2245063
  • September 2012
  • 42 pages
  • Global Markets Direct

Nonhematologic Malignancy – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Nonhematologic Malignancy - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Nonhematologic Malignancy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Nonhematologic Malignancy. Nonhematologic Malignancy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Nonhematologic Malignancy.
- A review of the Nonhematologic Malignancy products under READ MORE >

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Nonhematologic Malignancy Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Nonhematologic Malignancy 7
Nonhematologic Malignancy Therapeutics under Development by Companies 9
Nonhematologic Malignancy Therapeutics under Investigation by Universities/Institutes 10
Early Clinical Stage Products 11
Comparative Analysis 11
Nonhematologic Malignancy Therapeutics – Products under Development by Companies 12
Nonhematologic Malignancy Therapeutics – Products under Investigation by Universities/Institutes 13
Companies Involved in Nonhematologic Malignancy Therapeutics Development 14
Boehringer Ingelheim GmbH 14
Abbott Laboratories 15
Millennium Pharmaceuticals, Inc. 16
Celgene Corporation 17
Cytheris SA 18
Nonhematologic Malignancy – Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Combination Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
MLN-4924 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
sirolimus - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
CYT-99 007 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Veliparib + Temodar - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
BMS-188797 + Carboplatin - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
PF-04554878 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
TAK-733 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
TAK-960 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
TAK-441 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
BI-853520 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Nonhematologic Malignancy Therapeutics – Drug Profile Updates 37
Nonhematologic Malignancy Therapeutics – Discontinued Products 39
Nonhematologic Malignancy Therapeutics - Dormant Products 40
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 42
Disclaimer 42

List of Tables
Number of Products Under Development for Nonhematologic Malignancy, H2 2012 7
Products under Development for Nonhematologic Malignancy – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Early Clinical Stage Development, H2 2012 11
Products under Development by Companies, H2 2012 12
Products under Investigation by Universities/Institutes, H2 2012 13
Boehringer Ingelheim GmbH, H2 2012 14
Abbott Laboratories, H2 2012 15
Millennium Pharmaceuticals, Inc., H2 2012 16
Celgene Corporation, H2 2012 17
Cytheris SA, H2 2012 18
Assessment by Monotherapy Products, H2 2012 19
Assessment by Combination Products, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 24
Nonhematologic Malignancy Therapeutics – Drug Profile Updates 37
Nonhematologic Malignancy Therapeutics – Discontinued Products 39
Nonhematologic Malignancy Therapeutics – Dormant Products 40

List of Figures
Number of Products under Development for Nonhematologic Malignancy, H2 2012 7
Products under Development for Nonhematologic Malignancy – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Early Clinical Stage Products, H2 2012 11
Assessment by Monotherapy Products, H2 2012 19
Assessment by Combination Products, H2 2012 20
Assessment by Route of Administration, H2 2012 21
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Molecule Type, H2 2012 23
Assessment by Stage and Molecule Type, H2 2012 24

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos